# Allogene Therapeutics, Inc.: Form 8-K, filed May 13, 2026

- Company: [Allogene Therapeutics, Inc.](/companies/allo.md) (CIK 1737287)
- Form: 8-K
- Filed: 2026-05-13
- Accepted by EDGAR: May 13, 2026, 16:03 ET
- Period: 2026-05-12
- Accession: 0001628280-26-034583
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1737287/000162828026034583/allo-20260512.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1737287/000162828026034583/

## Items reported

- Item 1.01: Entry into a material agreement
- Item 1.02: Termination of a material agreement
- Item 2.02: Results of operations
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1737287/000162828026034583/allo-20260512.htm

Filed May 13, 2026.
Source: SEC EDGAR, the filing index for accession 0001628280-26-034583. Last ingested by Listed: Oct 27, 2026, 17:28 ET. No prices; not investment advice.